Dr Reddy’s Expands Gynaecology Offerings with $32.2 Million Acquisition of Mercury Pharma HRT Brands
Loading more articles...
Dr Reddy's acquires HRT brands from Mercury Pharma for $32.2 mn, boosts gynaecology
C
CNBC TV18•18-02-2026, 20:48
Dr Reddy's acquires HRT brands from Mercury Pharma for $32.2 mn, boosts gynaecology
•Dr Reddy's Laboratories Ltd acquired trademarks Progynova and CycloProgynova from Mercury Pharma Group Ltd for $32.15 million.
•The acquisition strengthens Dr Reddy's gynaecology portfolio and marks its entry into the hormone replacement therapy (HRT) segment in India.
•Progynova treats oestrogen deficiency symptoms and prevents postmenopausal osteoporosis; CycloProgynova offers combined oestrogen and progestogen therapy.
•Progynova is the No. 1 brand in the estradiol market in India, with sales of ₹100 crore as per IQVIA MAT December 2025 data.
•MV Ramana, CEO of Branded Markets, stated the acquisition will spearhead expansion into the HRT segment and bring first-in-class treatment to patients.
